Biology Reference
In-Depth Information
Burchett SK, McIntosh K, Walker BD. 2000. Functionally inert HIV-speci®c cytotoxic T lym-
phocytes do not play a major role in chronically infected adults and children. J Exp Med 192:
1819±1832.
Goulder PJ, Addo MM, Altfeld MA, Rosenberg ES, Tang Y, Govender U, Mngqundaniso N,
Annamalai K, Vogel TU, Hammond M, Bunce M, Coovadia HM, Walker BD. 2001a. Rapid
de®nition of ®ve novel HLA-A*3002-restricted human immunode®ciency virus-speci®c cyto-
toxic T-lymphocyte epitopes by Elispot and intracellular cytokine staining assays. J Virol 75:
1339±1347.
Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, Eldridge RL, Addo MM, He S,
Mukherjee JS, Phillips MN, Bunce M, Kalams SA, Sekaly RP, Walker BD, Brander C. 2001b.
Substantial di¨erences in speci®city of HIV-speci®c cytotoxic T cells in acute and chronic HIV
infection. J Exp Med 193: 181±194.
Haas G, Hosmalin A, Hadida F, Duntze J, Debre P, Autran B. 1997. Dynamics of HIV variants
and speci®c cytotoxic T-cell recognition in nonprogressors and progressors. Immunol Lett 57:
63±68.
Haas G, Samri A, Gomard E, Hosmalin A, Duntze J, Bouley JM, Ihlenfeldt HG, Katlama C,
Autran B. 1998. Cytotoxic T-cell responses to HIV-1 reverse transcriptase, integrase and pro-
tease. AIDS 12: 1427±1436.
Haase AT. 1999. Population biology of HIV-1 infection: viral and CD4
T cell demographics and
dynamics in lymphatic tissues. Annu Rev Immunol 17: 625±656.
Harty JT, Tvinnereim AR, White DW. 2000. CD8
T cell e¨ector mechanisms in resistance to in-
fection. Annu Rev Immunol 18: 275±308.
He X, Rehermann B, Boisvert J, Mumm J, Maecker H, Roederer M, Wright T, Maino V, Davis M,
Greenberg H. 2001. Direct functional analysis of epitope-speci®c CD8
T cells in peripheral
blood. Viral Immunol 14: 59±69.
Hutchings PR, Cambridge G, Tite JP, Meager T, Cooke A. 1989. The detection and enumeration of
cytokine-secreting cells in mice and man and the clinical application of these assays. J Immunol
Methods 120: 1±8.
Kelleher A, Carr A, Zaunders J, Cooper D. 1996. Alterations in the immune response of human
immunode®ciency virus (HIV)-infected subjects treated with an HIV-speci®c protease inhibitor,
ritonavir. J Infect Dis 173: 321±329.
Kern F, Surel IP, Brock C, Freistedt B, Radtke H, Sche¨old A, Blasczyk R, Reinke P, Schneider-
Mergener J, Radbruch A, Walden P, Volk HD. 1998. T-cell epitope mapping by ¯ow cytometry.
Nat Med 4: 975±978.
Kern F, Surel IP, Faulhaber N, Frommel C, Schneider-Mergener J, Schonemann C, Reinke P, Volk
HD. 1999. Target structures of the CD8()-T-cell response to human cytomegalovirus: the 72-
kilodalton major immediate-early protein revisited. J Virol 73: 8179±8184.
Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA, McCune
JM. 1998. Restoration of cytomegalovirus-speci®c CD4
T-lymphocyte responses after ganci-
clovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 4:
953±956.
Komanduri KV, Donahoe SM, Moretto WJ, Schmidt DK, Gillespie G, Ogg GS, Roederer M,
Nixon DF, McCune JM. 2001. Direct measurement of CD4
and CD8
T-cell responses to
CMV in HIV-1-infected subjects. Virology 279: 459±470.
Lederman M, Connick E, Landay A, et al. 1998. Clinical Trials Group Protocol 315. Immunologic
responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovu-
dine, lamivudine, and ritonavir: results of AIDS. J Infect Dis 178: 70±79.
Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. 1998. Long-lasting recovery
in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in ad-
vanced HIV-1 disease [see comments]. Lancet 351: 1682±1686.
